Accelerant Holdings
Insurance
Accelerant Holdings (ARX) Stock News
The latest ARX headlines and market coverage — 3 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
Tilray Medical Allemagne lance ARX™, une nouvelle marque de cannabis médicinal haut de gamme cultivé en Allemagne
Tilray Medical Germany has launched ARX™, a premium medical cannabis brand cultivated locally in Germany at its Aphria RX facility in Neumünster. The brand combines Broken Coast genetics with German cultivation expertise and strict European GMP standards, marking Tilray's first locally-developed premium medical cannabis brand in Germany. The product will be officially presented at Mary Jane Berlin 2026 and distributed nationally through CC Pharma and 14U Pharma.
- GlobeNewswire Inc.·
Tilray Medical Deutschland bringt ARX™ auf den Markt, eine neue Premium-Marke für medizinisches Cannabis aus deutschem Anbau
Tilray Medical Deutschland hat die Markteinführung von ARX™ angekündigt, einer neuen Premium-Marke für medizinisches Cannabis, die im Aphria RX-Werk in Neumünster entwickelt und angebaut wird. Die Marke kombiniert bewährte Genetik von Broken Coast mit deutschem Anbauknow-how und wird nach EU-GMP-Standards hergestellt. ARX wird auf der Mary Jane Berlin 2026 vorgestellt und über etablierte deutsche Vertriebskanäle wie CC Pharma und 14U Pharma vertrieben.
- Benzinga·
ECARX Announces First Quarter 2026 Unaudited Financial Results
LONDON , May 19, 2026 /PRNewswire/ -- ECARX Holdings Inc. (NASDAQ: ECX ) ("ECARX" or the "Company"), a leading global automotive intelligence company, today announced unaudited financial results for the quarter ended March 31, 2026. Ziyu Shen, ECARX CEO, commented, "The first quarter of 2026 was defined by continued disciplined execution and continued global momentum, demonstrating the underlying resilience of our core business. Despite traditional seasonality and a complex macroeconomic environment marked by memory component inflation, our disciplined execution mitigated the modest impact on our topline into meaningful profitability improvements. We successfully expanded our gross margin to 21.4% and nearly halved our operating loss from the same period last year. Perhaps most notably, we achieved our third consecutive quarter of positive adjusted EBITDA at US$4 million. This resilient performance is the direct result of the strategic framework we established late last year where our focus remains firmly on accelerating our globalization strategy, investing in our R&D roadmap, and optimizing our lean operating strategy to sustain profitability. R&D costs were down 32% YoY, driven by continued resource prioritization and the internal deployment of AI across our business to drive innovation while reducing structural costs. We are rapidly accelerating our transformation into a truly global technology leader. To support our expanding commercial footprint and align with global best practices, we have recently actively strengthened our corporate governance and leadership team, separating the roles of Chairperson and CEO and welcoming Lone Fønss Schrøder to lead our Board of Directors, alongside Dylan D. Jeng as our new Chief Financial Officer. With our offices in Singapore now fully operational, and the capital raised late last year actively being deployed, we are